GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: AVII
Buy

Sarepta Therapeutics Inc (NASDAQ: SRPT) rated to Buy by BofA/Merrill

Friday,  Oct 23, 2015  10:25 AM ET by Betsy O'Brien Harrison

BofA/Merrill rated Sarepta
Therapeutics Inc (NASDAQ: SRPT) to Buy.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

BofA/Merrill



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy